论文部分内容阅读
【目的】探讨切割修复交叉互补基因 2 (excisionrepaircross complementingrodentrepairdeficiencygene 2 ,ERCC2 )表达与人肿瘤对抗癌药耐药的关系。【方法】采用Westernblot检测美国国家癌症研究所 (NationalCancerInstitute,NCI)用于抗癌药筛选的 6 0株人肿瘤细胞的ERCC2表达 ,并与 170种抗癌药物的细胞毒试验结果进行相关性分析。【结果】肿瘤细胞ERCC2的蛋白表达水平高低不一 ,其中 6株细胞的ERCC2蛋白水平在可测定范围以下。 170种抗癌药物中有 2 8种化疗药物的耐药性与肿瘤细胞的ERCC2蛋白水平相关性显著或非常显著。根据药物作用机理分析 ,肿瘤细胞ERCC2表达与其对烷化剂和抗有丝分裂剂类抗癌药耐药相关性显著。【结论】肿瘤细胞具有DNA修复能力 ,如核苷酸切割修复 ,更具体是具有ERCC2基因表达将表现为对主要是烷化剂和抗有丝分裂剂类抗癌药的耐药
【Objective】 To investigate the relationship between excision repair cross complementing gene 2 (ERCC2) expression and the resistance of human tumors to anticancer drugs. 【Methods】 Western blot was used to detect the expression of ERCC2 in 60 human cancer cells screened by the National Cancer Institute (NCI) for anticancer drugs, and the correlation analysis was performed with the cytotoxicity test results of 170 anticancer drugs. [Results] The protein levels of ERCC2 in tumor cells were varied, and the ERCC2 protein levels of 6 cells were below the measurable range. Resistance of 28 chemotherapeutic agents among the 170 anticancer drugs was significantly or very significantly correlated with the ERCC2 protein level of tumor cells. According to the analysis of the mechanism of drug action, the expression of ERCC2 in tumor cells is significantly associated with resistance to alkylating agents and anti-cancer drug resistance against mitotic agents. [Conclusion] Tumor cells have DNA repairing ability, such as nucleotide cleavage repair, more specifically having ERCC2 gene expression will show resistance to mainly alkylating agents and anti-mitotic agents anticancer drugs.